These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36738264)

  • 1. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
    Al-Keilani MS; Almomani BA
    Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt.
    Khedr EM; Mahmoud DM; Hussein HB; Malky IEL; Mostafa SS; Gamea A
    Sci Rep; 2024 Mar; 14(1):7027. PubMed ID: 38528018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
    Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
    Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.
    Thach AV; Brown CM; Herrera V; Sasane R; Barner JC; Ford KC; Lawson KA
    Int J MS Care; 2018; 20(6):251-259. PubMed ID: 30568562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
    Burkhard A; Toliver J; Rascati K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
    Bawand R; Ghiasian M; Fathoallahi N; Moradi A
    Mult Scler Relat Disord; 2022 Jul; 63():103857. PubMed ID: 35597079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
    Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
    Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
    Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
    BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 15. The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis-Cross-Sectional Study.
    Kołtuniuk A; Pytel A; Krówczyńska D; Chojdak-Łukasiewicz J
    Int J Environ Res Public Health; 2022 Nov; 19(21):. PubMed ID: 36361427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world persistence of multiple sclerosis disease-modifying therapies.
    Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
    Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
    Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
    J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study.
    Giedraitiene N; Taluntiene V; Kaubrys G
    Sci Rep; 2022 Jul; 12(1):12447. PubMed ID: 35859004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis.
    Stratos K; McGarragle K; Thistle J; Vyas MV; Lee L
    Mult Scler Relat Disord; 2020 Jun; 41():102016. PubMed ID: 32135497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.